肝细胞癌诊疗指南（2019年版）
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).
作者信息
Zhou Jian, Sun Huichuan, Wang Zheng, Cong Wenming, Wang Jianhua, Zeng Mengsu, Zhou Weiping, Bie Ping, Liu Lianxin, Wen Tianfu, Han Guohong, Wang Maoqiang, Liu Ruibao, Lu Ligong, Ren Zhengang, Chen Minshan, Zeng Zhaochong, Liang Ping, Liang Changhong, Chen Min, Yan Fuhua, Wang Wenping, Ji Yuan, Yun Jingping, Cai Dingfang, Chen Yongjun, Cheng Wenwu, Cheng Shuqun, Dai Chaoliu, Guo Wenzhi, Hua Baojin, Huang Xiaowu, Jia Weidong, Li Yaming, Li Yexiong, Liang Jun, Liu Tianshu, Lv Guoyue, Mao Yilei, Peng Tao, Ren Weixin, Shi Hongcheng, Shi Guoming, Tao Kaishan, Wang Wentao, Wang Xiaoying, Wang Zhiming, Xiang Bangde, Xing Baocai, Xu Jianming, Yang Jiamei, Yang Jianyong, Yang Yefa, Yang Yunke, Ye Shenglong, Yin Zhengyu, Zhang Bixiang, Zhang Boheng, Zhang Leida, Zhang Shuijun, Zhang Ti, Zhao Yongfu, Zheng Honggang, Zhu Jiye, Zhu Kangshun, Liu Rong, Shi Yinghong, Xiao Yongsheng, Dai Zhi, Teng Gaojun, Cai Jianqiang, Wang Weilin, Cai Xiujun, Li Qiang, Shen Feng, Qin Shukui, Dong Jiahong, Fan Jia
机构信息
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Pathology, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
出版信息
Liver Cancer. 2020 Dec;9(6):682-720. doi: 10.1159/000509424. Epub 2020 Nov 11.
BACKGROUND
Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.
SUMMARY
Since the publication of in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years.
KEY MESSAGES
Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People's Republic of China in December 2019.
背景
原发性肝癌在中国约90%为肝细胞癌，是第四大常见恶性肿瘤和肿瘤相关死亡的第二大主要原因，对中国人民的生命健康构成重大威胁。
总结
自2018年[具体指南名称]发布以来，国内外出现了与肝癌诊断、分期及治疗相关的更多高质量证据，需要对指南进行更新。新版[具体指南名称]由中国肝癌领域70多位专家编写。它们反映了近年来中国在肝癌诊断和治疗方面的实际情况。
关键信息
最重要的是，新指南于2019年12月得到中华人民共和国国家卫生健康委员会医疗管理局的认可和颁布。
Zotero 插件